ProKidney to Participate in the Jefferies Global Healthcare Conference
ProKidney Corp. - Class A Ordinary Shares (PROK)
Company Research
Source: GlobeNewswire
WINSTON-SALEM, N.C., May 29, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that senior members of the management team will be participating in the Jefferies Global Healthcare Conference taking place from June 4 – 6, 2024 in New York, NY. The ProKidney management team will host one-on-one meetings during the event. Interested investors should contact their Jefferies representative to schedule meetings. About ProKidneyProKidney, a pioneer in the treatment of CKD through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney’s lead product candidate, rilparencel (also known as REACT®), is a first-of-its-kind, patented, proprietary autologous cellular therapy being evaluated to potentially preserve kidney function in diabetic patients at high risk of kidney failure. Rilparencel has received Regenerative M
Show less
Read more
Impact Snapshot
Event Time:
PROK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PROK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PROK alerts
High impacting ProKidney Corp. - Class A Ordinary Shares news events
Weekly update
A roundup of the hottest topics
PROK
News
- ProKidney Corp. (NASDAQ: PROK) is now covered by analysts at Guggenheim. They set a "buy" rating and a $6.00 price target on the stock.MarketBeat
- ProKidney drops Phase III CKD study to focus on US market and save up to $175m [Yahoo! Finance]Yahoo! Finance
- ProKidney Corp. (NASDAQ: PROK) had its price target lowered by analysts at Bank of America Co. from $4.00 to $3.00. They now have a "neutral" rating on the stock.MarketBeat
- ProKidney revises Phase 3 program for lead asset [Seeking Alpha]Seeking Alpha
- ProKidney Announces Strategic Updates to its Phase 3 Program to Accelerate Rilparencel's Registrational Path to Potential Approval in the U.S. [Yahoo! Finance]Yahoo! Finance
PROK
Earnings
- 8/9/24 - Beat
PROK
Sec Filings
- 9/20/24 - Form 4
- 9/19/24 - Form 144
- 9/16/24 - Form 4
- PROK's page on the SEC website